Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorVejselova, Djanan
dc.contributor.authorKutlu, Hatice Mehtap
dc.contributor.authorKuş, Gökhan
dc.contributor.authorKabadere, Selda
dc.contributor.authorUyar, Ruhi
dc.date.accessioned2019-10-20T08:00:48Z
dc.date.available2019-10-20T08:00:48Z
dc.date.issued2014
dc.identifier.issn1300-0152
dc.identifier.issn1303-6092
dc.identifier.urihttps://dx.doi.org/10.3906/biy-1405-36
dc.identifier.urihttps://hdl.handle.net/11421/16181
dc.descriptionWOS: 000345431100021en_US
dc.description.abstractFibrocarcinomas are malignant tumours that originate in mesenchymal cells. The tumours typically form in the presence of connective tissue and are of key consideration when assessing research priorities for future healthcare management. Ceramidase inhibitors, such as ceranib-2, have demonstrated capacity to interfere with cellular DNA functionality, initiating apoptosis in many cancer cell lines. The enzyme ceramidase can regulate cellular levels of sphingosine and sphingosine-1-phosphate by controlling hydrolysis of ceramide. The present study investigates the antigrowth effects of ceranib-2 on mouse embryonic fibroblast cells (NIH/3T3 normal cell line) and rat embryonic fibroblast cells (5RP7 cancer cell line). Research was conducted using colorimetric 3-(4,5-dimethylthiazol-2-yl)2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, confocal microscopy, and transmission electron microscopy. The results indicate that in vitro fibrocarcinomas have the potential to undergo apoptotic death when influenced by the antigrowth behaviour of ceranib-2. This is true even of cells exposed only to minimal doses of ceranib-2. Indicators of apoptotic death, specifically presentation of a pyknotic nucleus, were observed by confocal micrographs in treated cells double-stained with acridine orange and Alexa Fluor-488 Phalloidin. It is theorised that ceranib-2 will function in accordance with the antiproliferative activity of other acid ceramidases, ultimately resulting in the molecule's classification as a new antitumour agent.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK)en_US
dc.description.sponsorshipThanks to the Scientific and Technological Research Council of Turkey (TUBITAK) for the support provided to Djanan Vejselova.en_US
dc.language.isoengen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.isversionof10.3906/biy-1405-36en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCeramidase Inhibitoren_US
dc.subjectCeranib-2en_US
dc.subjectCancer Treatmenten_US
dc.subjectCytotoxicityen_US
dc.subjectApoptosisen_US
dc.titleCytotoxic and apoptotic effects of ceranib-2 offering potential for a new antineoplastic agent in the treatment of cancer cellsen_US
dc.typearticleen_US
dc.relation.journalTurkish Journal of Biologyen_US
dc.contributor.departmentAnadolu Üniversitesi, Fen Fakültesi, Biyoloji Bölümüen_US
dc.identifier.volume38en_US
dc.identifier.issue6en_US
dc.identifier.startpage916en_US
dc.identifier.endpage921en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorKutlu, Hatice Mehtap
dc.contributor.institutionauthorKuş, Gökhan


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster